You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
1 October 2024
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Heidelberg Pharma AG Announces Updated Guidance
23 September 2024
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
29 August 2024
Heidelberg Pharma AG: Walter Miller, buy
27 August 2024
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Annahme der Gewährung von 75.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg …
11 July 2024
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
21 June 2024
Heidelberg Pharma reports on the results of the Annual General Meeting 2024
18 June 2024
Heidelberg Pharma AG announces updated guidance
23 May 2024
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
13 May 2024
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 20.06.2024 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
25 April 2024
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
17 April 2024
5 April 2024
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
27 March 2024
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
26 March 2024
Heidelberg Pharma AG: Dr. Georg F. Baur, buy
25 March 2024
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
19 March 2024
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
18 March 2024
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
6 March 2024
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
4 March 2024
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
31 January 2024
Heidelberg Pharma AG: Walter Miller, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg Pharma AG. …
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg …
Heidelberg Pharma AG: Dr. Jan Schmidt-Brand, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg …
22 January 2024
18 December 2023
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy
29 November 2023
Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
15 November 2023
Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
10
Oct 24
Publication quarterly statement (call-date Q3)